For FTLD in particular, where clinical and pathological heterogeneity is great, biomarkers of tau pathology or TDP pathology would be pivotal for advancing the field by facilitating the distinction of the two major pathologies in FTD. Here, MAPT is linked to frontotemporal dementia.